EGFR and paronychia: S. aureus was identified in 90% of papulopustular and paronychia lesions associated with EGFR inhibitor therapy, with numerous strains demonstrating multidrug resistance (MDR)—particularly to β-lactams and tetracyclines—and a pronounced capacity for biofilm formation, especially in lesions exhibiting chronic progression.